Search academic texts

Information × Registration Number 0225U000853, (0123U100471) , R & D reports Title To develop an algorithm for immunological and molecular genetic monitoring of patients with Ph-negative myeloproliferative neoplasms in the induction of remission and in patients with Ph-positive chronic myeloid leukemia, who achieved remission with targeted drugs. popup.stage_title Провести скринінг показників, що відображають ступінь молекулярної відповіді на лікування у пацієнтів, які отримують підтримуюче лікування, та у пацієнтів при повній відміні лікування. Head Voroniak Myroslav I., Кандидат біологічних наукMasliak Zvenyslava V., Доктор медичних наук Registration Date 20-01-2025 Organization State institution "Institute of blood pathology and transfusion medicine of Nataional Academy of Medical scinces of Ukraine" popup.description1 To develop a system for monitoring of the course of chronic myeloproliferative neoplasias based on the study of immunological and molecular genetic markers of a tumor process, to establish risk factors for the progression of the disease in patients during discontinuation of drug therapy and the occurrence of complications on the background of the use of targeted and immunomodulatory drugs. popup.description2 Identification of leukemic stem cells (LSC) by flow cytometry in patients with different duration of treatment with tyrosine kinase inhibitors (TKI) and deep molecular genetic response (DMR) showed that the pool of leukemic stem cells (LSC) circulates in the blood, which is a risk factor of disease relapse after stopping TKI use. Routine molecular monitoring of DMR by PCR in patients who are candidates for discontinuation of treatment should be supplemented by immunophenotypic determination of LSC, as it is accessible, rapid and inexpensive. In patients who are going to stop TKI treatment or are already in treatment-free remission (TFR), with an increase in the LSC pool, even with the maintenance of molecular remission, it is advisable to carry out a genetic study by the NGS method to detect additional gene mutations and, if necessary, to perform early correction of the therapeutic tactics. Product Description popup.authors Boiko Olha I. Danysh Olha Yo. Kokoruz Mar'iana V. Melnyk Mariia I. Simonova Mar'iana I. Tomashevska Nataliia Ya. Thir Hrystyna R Khudzii Sofiia S. Shelep Nataliia V. Shurko Nataliia O popup.nrat_date 2025-01-20 Close